Aminophylline 225mg modified-release tablets
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Aminophylline
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aminophylline
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
WHO defined daily dose (DDD)
600 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Aminophylline
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
7-9 hours
Mechanism
Aminophylline is the ethylenediamine salt of theophylline.
Food interactions
6 warnings
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
7-9 hours
Protein binding
60%
Volume of distribution
0.3 to 0.7 L/kg
Clearance
0.29 mL
* 0.64 mL/kg/min [postnatal age 25-57 days]
* 1.7…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 924 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
* 0.64 mL/kg/min [postnatal age 25-57 days]
* 1.7 mL/kg/min [ 1-4 years]
* 1.6 mL/kg/min [4-12 years]
* 0.9 mL/kg/min [13-15 years]
* 1.4 mL/kg/min [16-17 years]
* 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics]
* 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function]
* 0.33 mL/kg/min [Acute pulmonary edema]
* 0.54 mL/kg/min [COPD->60 years, stable non-smoker >1 year]
* 0.48 mL/kg/min [COPD with cor pulmonale]
* 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
* 0.31 mL/kg/min [Liver disease -cholestasis]
* 0.35 mL/kg/min [cirrhosis]
* 0.65 mL/kg/min [acute hepatitis]
* 0.47 mL/kg/min [Sepsis with multi-organ failure]
* 0.38 mL/kg/min [hypothyroid]
* 0.8 mL/kg/min [hyperthyroid]
Proteins and enzymes this drug interacts with in the body
PMID:1315035 PMID:25961942 PMID:8155697 PMID:8695850
Also has activity toward cUMP .
PMID:27975297
Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling PMID:31420216 PMID:34707099
PMID:28497810
Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events (By similarity). Histone deacetylases act via the formation of large multiprotein complexes (By similarity). Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR .
PMID:12724404
Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development (By similarity).
Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin .
PMID:16428440 PMID:28977666
Component of the SIN3B complex that represses transcription and counteracts the histone acetyltransferase activity of EP300 through the recognition H3K27ac marks by PHF12 and the activity of the histone deacetylase HDAC2 .
PMID:37137925
Also deacetylates non-histone targets: deacetylates TSHZ3, thereby regulating its transcriptional repressor activity .
PMID:19343227
May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation (By similarity). Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A .
PMID:21965678
In addition to protein deacetylase activity, also acts as a protein-lysine deacylase by recognizing other acyl groups: catalyzes removal of (2E)-butenoyl (crotonyl), lactoyl (lactyl) and 2-hydroxyisobutanoyl (2-hydroxyisobutyryl) acyl groups from lysine residues, leading to protein decrotonylation, delactylation and de-2-hydroxyisobutyrylation, respectively PMID:28497810 PMID:29192674 PMID:35044827
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC R03DA55
ATC R03DA05
ATC R03DA20
ATC R03DB05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Aminophylline
Additional database identifiers
Drugs Product Database (DPD)
9963
ChemSpider
9062
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8778
GenAtlas
PDE3A
GeneCards
PDE3A
GenBank Gene Database
M91667
GenBank Protein Database
38201493
Guide to Pharmacology
1298
UniProt Accession
PDE3A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:262
GenAtlas
ADORA1
GeneCards
ADORA1
GenBank Gene Database
S45235
GenBank Protein Database
256155
Guide to Pharmacology
18
UniProt Accession
AA1R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:268
GenAtlas
ADORA3
GeneCards
ADORA3
GenBank Gene Database
L20463
GenBank Protein Database
349449
Guide to Pharmacology
21
UniProt Accession
AA3R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4853
GenAtlas
HDAC2
GeneCards
HDAC2
GenBank Gene Database
U31814
GenBank Protein Database
1667394
Guide to Pharmacology
2616
UniProt Accession
HDAC2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2631
GeneCards
CYP2E1
GenBank Gene Database
J02625
GenBank Protein Database
181360
Guide to Pharmacology
1330
UniProt Accession
CP2E1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2596
GenAtlas
CYP1A2
GeneCards
CYP1A2
GenBank Gene Database
Z00036
Guide to Pharmacology
1319
UniProt Accession
CP1A2_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: